ERBB2 and breast cancer: The analysis of the various studies carried out by TCGA for the characterization of the molecular abnormalities of breast cancers provided evidence that the NOTCH pathway exhibited frequent alterations in breast cancer basal (38%), followed by luminal B (25%), HER2-enriched (18%), and luminal A (14%) and BRCA normal (3%) [368].